Business Standard

Saturday, December 21, 2024 | 06:47 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

True North to pick 2.44% stake for Rs 536.25 crore in Biocon Biologics

Deal values Biocon Biologics at $ 3 billion

Ban on upfront commission, uncertainty in equity markets hit new offers
Premium

Vinay Umarji Ahmedabad
Private equity (PE) player True North is set to pick up a minority 2.44 per cent stake for Rs 536.25 crore in Biocon Biologics India Ltd., subsidiary of the Bengaluru-based global biopharmaceuticals company Biocon Ltd. 

Biocon Biologics' Board of Directors on Monday approved the primary equity investment by True North, with the deal valuing the company at Rs 21450 crore or $3 billion on a pre-money equity basis. According to an official communique by the company, True North's will invest in the biosimilars business post all restructuring, including the filed merger of Biocon Research Ltd with Biocon Biologics.

The transaction is subject
Topics : True North

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in